[Clinical studies of cefpiramide in obstetrics and gynecology].
In vivo transfer and therapeutic efficiency of a new cephalosporin derivative, cefpiramide (CPM) have studied in perinatal and gynecologic field. The following results have been obtained. The level of CPM transferred to uterus and adnexa was higher than its MIC against majority of Gram-negative bacilli, such as E. coli. This drug as demonstrated its efficiency, in treating 3 infection cases refractory to cephalothin, ampicillin and cephalexin, out of which 1 had "excellent" and 2 had "good" results. No side effect was evidenced in any of our patients. In conclusion, this drug has satisfactory tissue transfer as well as sufficient safety and excellent efficiency in treatment of perinatal infection cases.
D000290:Adnexa Uteri / Q000378:metabolism; D000328:Adult; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D002511:Cephalosporins / Q000378:metabolism / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D005260:Female; D005322:Premature Rupture of Fetal Membranes / Q000150:complications; D005831:Genital Diseases, Female / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D007044:Hysterectomy; D007700:Kinetics; D011247:Pregnancy; D014599:Uterus / Q000378:metabolism
D002511:Cephalosporins; C036666:cefpiramide